Collaboration combines Mission’s unique science, chemistry and proprietary enzyme platform with AbbVie’s strong neurodegenerative disease research, development and commercialisation capabilities CAMBRIDGE, UK and NORTH CHICAGO, ILL, USA – 15th November 2018 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) and AbbVie (“AbbVie”)(NYSE: ABBV), a research-based global … Continue reading Mission Therapeutics and AbbVie sign DUBs Collaboration in Alzheimer’s and Parkinson’s Disease